ARQT (Arcutis Biotherapeutics) Tariff Resilience Score: 7/10 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARQT Arcutis Biotherapeutics Inc ARQT
56 GF Score
Price $24.83
GF Value $30.59
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Arcutis Biotherapeutics Tariff Resilience Score?

Arcutis Biotherapeutics ARQT -2.09% 56 Tariff Resilience Score is 7 as of Aug. 21, 2026. GuruFocus rates ARQT with a GF Score™ of 56/100 and a GF Value™ of $30.59 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,362 Biotechnology companies, Arcutis Biotherapeutics ranks better than 90.31% on this metric.

Arcutis Biotherapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Arcutis Biotherapeutics has Arcutis Biotherapeutics Inc relies on specialized pharmaceutical ingredients, which may face some tariff risks. However, its primary market is domestic, and it has strong pricing power to mitigate potential cost increases.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Arcutis Biotherapeutics might have Highly Resilient.

Arcutis Biotherapeutics  (NAS:ARQT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Arcutis Biotherapeutics Tariff Resilience Score Related Terms

ARQT vs IDYA, NAMS, ALMS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Arcutis Biotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcutis Biotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Tariff Resilience Score falls into.


ARQT
56GF Score
Arcutis Biotherapeutics Inc ARQT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Arcutis Biotherapeutics (ARQT) has a Tariff Resilience Score of 7 as of Aug. 21, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Arcutis Biotherapeutics ranks #132 out of 1362 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Arcutis Biotherapeutics' Tariff Resilience Score too high?
Arcutis Biotherapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Arcutis Biotherapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Arcutis Biotherapeutics ranks #132 out of 1362 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcutis Biotherapeutics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arcutis Biotherapeutics' Tariff Resilience Score compare to IDYA and NAMS?
According to the Biotechnology industry distribution chart, Arcutis Biotherapeutics ranks #132 out of 1362 companies for Tariff Resilience Score. This places Arcutis Biotherapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Arcutis Biotherapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,362 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcutis Biotherapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcutis Biotherapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcutis Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arcutis Biotherapeutics (ARQT) is currently considered Modestly Undervalued. The stock's GF Value™ is $30.59, compared to a current price of $24.83 — trading 18.8% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Arcutis Biotherapeutics' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Arcutis Biotherapeutics (ARQT), the current Tariff Resilience Score is 7 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued. The current stock price of $24.83 is trading 18.8% below its estimated GF Value™ of $30.59. GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.

Key valuation signals for ARQT:

  • Tariff Resilience Score: 7
  • GF Value™: $30.59 vs. price of $24.83 (18.8% below fair value)
  • GF Score™: 56/100 with 2 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1362)

No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcutis Biotherapeutics Business Description

Address 3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score

Get the complete analysis for ARQT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.83
Price
$30.59
GF Value